DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Inflammatory Conditions – Cosentyx Drug Quantity Management Policy – Per Days

- Cosentyx® (secukinumab subcutaneous injection – Novartis)

REVIEW DATE: 12/16/2022

OVERVIEW

Cosentyx, an interleukin (IL)-17A antagonist, is indicated in the following conditions:[1]

- **Plaque psoriasis**, in patients ≥ 6 years of age with moderate to severe disease who are candidates for systemic therapy or phototherapy.
- **Psoriatic arthritis**, in patients ≥ 2 years of age with active disease.
- **Ankylosing spondylitis**, in adults with active disease.
- **Non-radiographic axial spondyloarthritis**, in adults with active disease and objective signs of inflammation.
- **Enthesitis-related arthritis** in patients ≥ 4 years of age with active disease.

Dosing

Cosentyx is administered by subcutaneous (SC) injection.[1] When a 300 mg dose is needed, it should be given as two 150 mg SC injections at separate sites.

- **Ankylosing Spondylitis:** Administer with or without a loading dose.
  - <u>With a loading dose</u>: 150 mg at Weeks 0, 1, 2, 3, and 4, then 150 mg once every 4 weeks (Q4W) thereafter.
  - <u>Without a loading dose</u>: 150 mg Q4W.
  - If the patient continues to have active ankylosing spondylitis, consider 300 mg Q4W.
- **Plaque Psoriasis:**
  - <u>Adults</u>: 300 mg at Weeks 0, 1, 2, 3, and 4, followed by 300 mg Q4W. For some patients, 150 mg Q4W may be acceptable.
  - <u>Pediatric patients ≥ 6 years of age</u>: Dose is based on body weight and is administered at Weeks 0, 1, 2, 3, and 4 followed by Q4W dosing. The dose is 75 mg for patients weighing < 50 kg and is 150 mg for patients weighing ≥ 50 kg.
- **Psoriatic Arthritis:** Cosentyx may be administered with or without methotrexate.
  - <u>Adults with coexistent moderate to severe plaque psoriasis</u>: Use the dosing and administration recommendations for plaque psoriasis.
  - <u>Other adults with psoriatic arthritis</u>: Administer with or without a loading dose.
    - <u>With a loading dose</u>: 150 mg at Weeks 0, 1, 2, 3, and 4, then 150 mg Q4W thereafter.
    - <u>Without a loading dose</u>: 150 mg Q4W.
    - If the patient continues to have active psoriatic arthritis, consider 300 mg Q4W.
  - <u>Pediatric patients ≥ 2 years of age</u>: Dose is based on body weight and is administered at Weeks 0, 1, 2, 3, and 4 followed by Q4W dosing. The dose is 75 mg for patients weighing ≥ 15 kg and < 50 kg and is 150 mg for patients weighing ≥ 50 kg.
- **Non-radiographic axial spondyloarthritis:** Administer with or without a loading dose.
  - <u>With a loading dose</u>: 150 mg at Weeks 0, 1, 2, 3, and 4, then 150 mg Q4W thereafter.
  - <u>Without a loading dose</u>: 150 mg Q4W.
- **Enthesitis-related arthritis:** Dose is based on body weight and is administered at Weeks 0, 1, 2, 3, and 4 followed by Q4W dosing. The dose is 75 mg for patients weighing ≥ 15 kg and < 50 kg and is 150 mg for patients weighing ≥ 50 kg.

Availability

Cosentyx is available in the following forms:

- 150 mg/mL single-dose Sensoready pen (cartons contain either one or two pens).
- 150 mg/mL single-dose prefilled syringe (cartons contain either one or two prefilled syringes).
- 75 mg/0.5 mL single-dose prefilled syringe (cartons contain one prefilled syringe) [for pediatric patients who weigh < 50 kg].

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Cosentyx, and to manage potential premature dose escalation. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration unless otherwise noted below.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per 28 Days	Home Delivery Maximum Quantity Per 84 Days
Cosentyx® (secukinumab subcutaneous injection)	150 mg/mL prefilled syringe	2 prefilled syringes	6 prefilled syringes
	150 mg/mL Sensoready pen	2 pens	6 pens
	75 mg/0.5 mL prefilled syringe	1 prefilled syringe	3 prefilled syringes

CRITERIA

Cosentyx 150 mg prefilled syringes or Sensoready pens

1. If the patient is initiating treatment or requires additional induction dosing for ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriatic arthritis, or enthesitis-related arthritis as verified by the absence of claims for Cosentyx in the past 130 days, approve a one-time override for 5 prefilled syringes or pens at retail or 7 prefilled syringes or pens at home delivery.

2. If the patient is initiating treatment or requires additional induction dosing for plaque psoriasis, as verified by the absence of claims for Cosentyx in the past 130 days, approve a one-time override for 10 prefilled syringes or pens at retail or 12 prefilled syringes or pens at home delivery.

Cosentyx 75 mg prefilled syringes

1. If the patient is initiating treatment or requires additional induction dosing for plaque psoriasis, psoriatic arthritis, or enthesitis-related arthritis, as verified by the absence of claims for Cosentyx in the past 130 days, approve a one-time override for 5 prefilled syringes at retail or 6 prefilled syringes or pens at home delivery.

REFERENCES

1. Cosentyx® subcutaneous injection [prescribing information]. East Hanover, NJ: Novartis; December 2021.